{"id":13,"date":"2018-08-13T21:27:21","date_gmt":"2018-08-13T21:27:21","guid":{"rendered":"https:\/\/lab.research.sickkids.ca\/waters\/?page_id=13"},"modified":"2024-01-17T15:26:00","modified_gmt":"2024-01-17T19:26:00","slug":"publications","status":"publish","type":"page","link":"https:\/\/lab.research.sickkids.ca\/waters\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

[vc_row][vc_column][vc_tta_tabs][vc_tta_section title=”2023″ tab_id=”1534195703555-ccd9cf81-3008″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

How Three Self-Secreted Biofilm Exopolysaccharides of Pseudomonas aeruginosa<\/em>, Psl, Pel, and Alginate, Can Each Be Exploited for Antibiotic Adjuvant Effects in Cystic Fibrosis Lung Infection<\/p>\n

<\/div><\/div>[vc_column_text]2023 May[\/vc_column_text][vc_column_text]Jonathan Chung, Shafinaz Eisha, Subin Park, Amanda J. Morris, Isaac Martin[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][\/vc_tta_section][vc_tta_section title=”2022″ tab_id=”1705518596446-9e4e9c2e-eeae”][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
Pseudomonas aeruginosa<\/em> aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis<\/div><\/div>[vc_column_text]2022 Dec[\/vc_column_text][vc_column_text]Amanda J. Morris, Yvonne C. W. Yau, Subin Park, Shafinaz Eisha, Nancy McDonald, Matthew R. Parsek, P. Lynne Howell, Lucas R. Hoffman, Dao Nguyen, Antonio DiGiandomenico, Ashley M. Rooney, Bryan Coburn, Lucia Grana-Miraglia, Pauline Wang, David S. Guttman, Daniel J. Wozniak & Valerie J. Waters[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][\/vc_tta_section][vc_tta_section title=”2021″ tab_id=”1705518535429-39a4db9c-92cb”][vc_row_inner][vc_column_inner width=”1\/2″]
<\/div>
<\/p>\n

Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways<\/p>\n

<\/div><\/div>[vc_column_text]2021 Feb[\/vc_column_text][vc_column_text]Martin I, Waters V, Grasemann H[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates<\/p>\n

<\/div><\/div>[vc_column_text]2021 Apr[\/vc_column_text][vc_column_text]Clark ST, Stapleton PJ, Wang PW, Yau YCW, Waters VJ, Hwang DM, Guttman DS[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

The role of Psl in the failure to eradicate Pseudomonas aeruginosa<\/em> biofilms in children with cystic fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2021 Aug[\/vc_column_text][vc_column_text]Amanda J. Morris, Lindsay Jackson, Yvonne CW Yau, Courtney Reichhardt, Trevor Beaudoin, Stephanie Uwumarenogie, Kevin M. Guttman, P. Lynne Howell, Matthew R. Parsek, Lucas R. Hoffman, Dao Nguyen, Antonio DiGiandomenico, David S. Guttman, Daniel J. Wozniak & Valerie J. Waters[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
Isolation of Total RNA from Pseudomonas aeruginosa<\/em> within Biofilms for Measuring Gene Expression<\/div><\/div>[vc_column_text]2021 Sep[\/vc_column_text][vc_column_text]Kevin Guttman, Pauline Wang, Lindsay Jackson, Amanda Morris, Yvonne Yau, Valerie Waters[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][\/vc_tta_section][vc_tta_section title=”2020″ tab_id=”1625766992972-3a884bd4-9032″][vc_row_inner][vc_column_inner width=”1\/2″]
<\/div>
<\/p>\n

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software<\/p>\n

<\/div><\/div>[vc_column_text]2020 Dec[\/vc_column_text][vc_column_text]Morris AJ, Li A, Jackson L, Yau YCW, Waters V[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways<\/p>\n

<\/div><\/div>[vc_column_text]2020 Dec[\/vc_column_text][vc_column_text]Khanolkar RA, Clark ST, Wang PW, Hwang DM, Yau YCW, Waters VJ, Guttman DS[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Clinical Outcomes Associated with\u00a0Burkholderia cepacia<\/i>\u00a0Complex Infection in Patients with Cystic Fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2020 Dec[\/vc_column_text][vc_column_text]Somayaji R, Yau YCW, Tullis E, LiPuma JJ, Ratjen F, Waters V<\/p>\n

[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients<\/p>\n

<\/div><\/div>[vc_column_text]2020 Dec[\/vc_column_text][vc_column_text]Jackson L, DePas W, Morris AJ, Guttman K, Yau YCW, Waters V[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Pseudomonas aeruginosa strain sharing in early infection among children with cystic fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2020 Jun[\/vc_column_text][vc_column_text]Stapleton PJ, Izydorcyzk C, Clark S, Blanchard A, Wang PW, Yau Y, Waters V, Guttman DS[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Burkholderia cenocepacia<\/i>\u00a0ET12 transmission in adults with cystic fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2020 Jan[\/vc_column_text][vc_column_text]Blanchard AC, Tang L, Tadros M, Muller M, Spilker T, Waters VJ, LiPuma JJ, Tullis E[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=”2019″ tab_id=”1625766986245-c0ec6f41-ac62″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Microbiology of Cystic Fibrosis Airway Disease<\/p>\n

<\/div><\/div>[vc_column_text]2019 Dec[\/vc_column_text][vc_column_text]Blanchard AC, Waters VJ[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2019 Jul[\/vc_column_text][vc_column_text]Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections<\/p>\n

<\/div><\/div>[vc_column_text]2019 Oct[\/vc_column_text][vc_column_text]Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with \u03b2-lactams<\/p>\n

<\/div><\/div>[vc_column_text]2019 Jan[\/vc_column_text][vc_column_text]Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE, Guttman DS, Hwang DM[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=”2018″ tab_id=”1625767029603-a1f8c4c8-4876″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population.<\/p>\n

<\/div><\/div>[vc_column_text]2018 Jul[\/vc_column_text][vc_column_text]Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance.<\/p>\n

<\/div><\/div>[vc_column_text]2018 Jun[\/vc_column_text][vc_column_text]Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2018 May[\/vc_column_text][vc_column_text]Waters V, Grimwood K[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.<\/p>\n

<\/div><\/div>[vc_column_text]2018 Mar[\/vc_column_text][vc_column_text]Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=”2017″ tab_id=”1534264804555-d4852a62-8915″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Dec[\/vc_column_text][vc_column_text]Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, Waters V[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Dec[\/vc_column_text][vc_column_text]Singh M, Yau YCW, Wang S, Waters V, Kumar A.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Oct[\/vc_column_text][vc_column_text]Waters V, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Sep[\/vc_column_text][vc_column_text]Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Jul[\/vc_column_text][vc_column_text]<\/p>\n

Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E.<\/p>\n

[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Jun[\/vc_column_text][vc_column_text]Waters V, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Feb[\/vc_column_text][vc_column_text]<\/p>\n

Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F.<\/p>\n

[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Apr[\/vc_column_text][vc_column_text]Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients.<\/p>\n

<\/div><\/div>[vc_column_text]2017 Jan[\/vc_column_text][vc_column_text]Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=”2016″ tab_id=”1534264809579-c7d5bbca-3ee5″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Dec[\/vc_column_text][vc_column_text]Waters V, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Dec[\/vc_column_text][vc_column_text]Beaudoin T, Kennedy S, Yau Y, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner][vc_separator border_width=”3″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Oct[\/vc_column_text][vc_column_text]Waters V, Stanojevic S, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Jul[\/vc_column_text][vc_column_text]Amin R, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Infections With Biofilm Formation: Selection of Antimicrobials and Role of Prolonged Antibiotic Therapy.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Jun[\/vc_column_text][vc_column_text]Beaudoin T, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Mar[\/vc_column_text][vc_column_text]Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.<\/p>\n

<\/div><\/div>[vc_column_text]2016 Jan[\/vc_column_text][vc_column_text]Tom SK, Yau YC, Beaudoin T, LiPuma JJ, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=”2015″ tab_id=”1534264811770-bf5ebceb-9cdd”][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Dec[\/vc_column_text][vc_column_text]Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Pulmonary Exacerbations in Children with Cystic Fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Nov[\/vc_column_text][vc_column_text]Waters V, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Nov[\/vc_column_text][vc_column_text]Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Nov[\/vc_column_text][vc_column_text]Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Oct[\/vc_column_text][vc_column_text]Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Cystic fibrosis microbiology: Advances in antimicrobial therapy.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Sep[\/vc_column_text][vc_column_text]Waters V, Smyth A.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Sep[\/vc_column_text][vc_column_text]Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau YC, Waters VJ, Hwang DM, Guttman DS.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis<\/p>\n

<\/div><\/div>[vc_column_text]2015 Jun[\/vc_column_text][vc_column_text]Clark ST, Diaz Caballero J, Cheang M, Coburn B, Wang PW, Donaldson SL, Zhang Y, Liu M, Keshavjee S, Yau YC, Waters VJ, Elizabeth Tullis D, Guttman DS, Hwang DM.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Lung microbiota across age and disease stage in cystic fibrosis.<\/p>\n

<\/div><\/div>[vc_column_text]2015 May[\/vc_column_text][vc_column_text]Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, Zhang Y, Surendra A, Gong Y, Elizabeth Tullis D, Yau YC, Waters VJ, Hwang DM, Guttman DS.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Mar[\/vc_column_text][vc_column_text]Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][vc_separator border_width=”3″][vc_row_inner][vc_column_inner width=”1\/2″]

<\/div>
<\/p>\n

In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.<\/p>\n

<\/div><\/div>[vc_column_text]2015 Jan[\/vc_column_text][vc_column_text]Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.[\/vc_column_text]\n\t \t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tRead More<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t<\/span>[\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_tabs][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1625769719428{padding-right: 20px !important;padding-left: 20px !important;}”]<\/p>\n

To see the full list of publications, please click on the button below:<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]